Skip to Content

Here’s Why Biotech Stocks Are Soaring

Dow Starts Week Off With Sharp Gains, Closing Over 250 Points HigherDow Starts Week Off With Sharp Gains, Closing Over 250 Points Higher
NEW YORK, NY - MARCH 30: Traders work on the floor of the New York Stock Exchange during the afternoon of March 30, 2015 in New York City. The Dow Jones Industrial Average rose sharply this morning, eventually closing out over 260 points higher. (Photo by Andrew Burton/Getty Images)Photo by Andrew Burton — Getty Images

U.S. biotech shares on Tuesday posted their best overall day since October, helped by a big upswing in the broader U.S. stock market.

The Nasdaq Biotechnology index climbed 4.3%, its biggest single-day percentage gain since October 15, as Wall Street enjoyed its strongest day in a month. Shares of large biotech companies, such as Amgen, Celgene, and Biogen, rallied at least 4%.

The gains came even as Hillary Clinton was poised to solidify her grasp on the Democratic presidential nomination during Super Tuesday contests, ahead of the general U.S. presidential election in November.

Clinton’s comments about reining in drug pricing have pressured shares of biotech and pharmaceutical companies, including a Tweet in September about “price gouging” that sent shares swooning.

Just on Tuesday, Clinton unveiled a new television advertisement about her willingness to take on predatory drug pricing and criticizing Valeant Pharmaceuticals International. Shares of Valeant (VRX) closed down 0.5%.

Even with Tuesday’s gains, the biotech index is off 21.6% in 2016, a far steeper decline than the 3.2% fall for the broader S&P 500 index and a 6.3% drop for the S&P health care sector.

The move by investors away from riskier assets combined with the cloud of potential pricing actions has led to pressure on biotech shares, which as a group had generally enjoyed a six-year run of gains up to last July.